CD5 INHIBITION AS A GENERALIZABLE STRATEGY TO AMPLIFY T CELL-MEDIATED ANTI-TUMOR EFFECTS OF BISPECIFIC T-CELL ENGAGERS

EHA Library, Weilin Wang, 4206658

NANOLEUKEMIA - A HIERARCHICAL CLASSIFICATION FRAMEWORK FOR HEMATOPOIETIC NEOPLASMS INTEGRATING EPIGENETIC AND GENETIC INFORMATION FROM WHOLE GENOME NANOPORE SEQUENCING

EHA Library, Maximilian Schönung, 4206887

NANOPORE-BASED GENOMIC AND EPIGENOMIC PROFILING FOR PEDIATRIC HEMATOLOGIC MALIGNANCIES USING TARGETED ADAPTIVE SAMPLING LONG-READ SEQUENCING: INTERIM REPORT OF THE JCCG-WGS STUDY

EHA Library, Shota Kato, 4206886

MORTALITY TRENDS OF HEMATOLOGICAL MALIGNANCIES AND THOSE COMPLICATED BY PULMONARY EMBOLISM: A NATIONWIDE POPULATION-BASED STUDY

EHA Library, Xi Quan, 4206878

HEAVY MENSTRUAL BLEEDING IN MILD-TO-MODERATE BLEEDING DISORDERS: INVESTIGATING PREVALENCE AND RISK-FACTORS USING MACHINE LEARNING

EHA Library, Tim Dreier, 4206876

DYSREGULATED CELLULAR CROSSTALK BETWEEN CD4+ T AND B CELLS IN ACQUIRED HEMOPHILIA A REVEALED BY SINGLE-CELL ANALYSIS

EHA Library, Enhao Li, 4206875

LONG-TERM OUTCOMES OF NATURALLY SELECTED CD7 CAR-T THERAPY IN RELAPSED/REFRACTORY T-LYMPHOBLASTIC LEUKEMIA/LYMPHOMA: A COHORT OF 171 PATIENTS

EHA Library, Xian Zhang, 4206664

IMPROVING EFFICACY AND SAFETY OUTCOMES IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN MORPHOLOGIC REMISSION TREATED WITH OBECABTAGENE AUTOLEUCEL (OBE-CEL)

EHA Library, Claire Roddie, 4206667

SAFETY AND EFFICACY OF UCART22 IN HEAVILY PRE-TREATED PATIENTS WITH RELAPSED OR REFRACTORY CD22+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL): RESULTS OF THE PHASE 1 BALLI-01 TRIAL

EHA Library, Nitin Jain, 4206668

UPFRONT CYDRI IS MORE EFFECTIVE FOR THE TREATMENT OF ACQUIRED HEMOPHILIA A THAN TRADITIONAL ORAL IMMUNOSUPPRESSION

EHA Library, Imre Bodó, 4206874

ETAVOPIVAT IMPROVES HEMOGLOBIN LEVELS IN ADULTS AND ADOLESCENTS WITH NON-TRANSFUSION-DEPENDENT ALPHA- OR ΒETA-THALASSEMIA: RESULTS FROM THE OPEN-LABEL PHASE 2 GLADIOLUS STUDY

EHA Library, Sujit Sheth, 4206851

ALLOGENEIC HSCT FOR TP53-ABERRANT MYELOID NEOPLASMS: REAL-WORLD OUTCOMES FROM A SCANDINAVIAN MULTICENTRE COHORT

EHA Library, Anders Eivind Myhre, 4206827

A LIVING THERAPEUTIC PLATFORM FOR LOCALIZED IN SITU MODULATION OF MACROPHAGE PYROPTOSIS AMELIORATES GVHD WHILE PRESERVING GVL

EHA Library, Zhuo Wan, 4206818

INTEGRATIVE MULTIMODAL PROFILING OF THE MICROBIOME-IMMUNE AXIS IN AUTOLOGOUS STEM CELL RECIPIENTS

EHA Library, Sabrina Becker, 4206815

INTEGRATED METABOLIC AND EPIGENETIC PROFILING UNCOVERS DISTINCT IMMUNE‑ESCAPE PROGRAMS AND TARGETABLE VULNERABILITIES IN POST‑TRANSPLANT AML RELAPSE

EHA Library, Annalisa Tameni, 4206814

CD20:CD3 T-CELL BISPECIFIC ANTIBODIES REPROGRAM THE TUMOR MICROENVIRONMENT AND SYNERGIZE WITH LYMPHOMA-TARGETED 4-1BB CO-STIMULATION IN PRECLINICAL DLBCL MODELS

EHA Library, Sergio Roa, 4206806

INTEGRATIVE PROTEOMICS IDENTIFIES DISTINCT SUBGROUPS AND ACTIONABLE SIGNALING PATHWAYS IN RICHTER TRANSFORMATION

EHA Library, Julien Broseus, 4206805

EFFICACY AND SAFETY OF BEZUCLASTINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS: PRIMARY RESULTS FROM THE APEX STUDY

EHA Library, Daniel J. DeAngelo, 4206771

MUTANT CALRETICULIN–SPECIFIC MONOCLONAL ANTIBODY, INCA033989, IS WELL TOLERATED AND ACHIEVES ROBUST SPLEEN, ANEMIA, AND MOLECULAR RESPONSES IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF)

EHA Library, Claire HARRISON, 4206770

SINGLE-CELL GENETIC LINEAGE TRACING REVEALS PRE-EXISTING BLAST CRISIS-INITIATING CLONES AT CHRONIC PHASE CML DIAGNOSIS

EHA Library, Elaine Cao, 4206709

SINGLE-CELL TRANSCRIPTOMICS-GUIDED FLOW CYTOMETRIC ANALYSIS OF INFLAMED MEGAKARYOCYTIC AND LYMPHOID PROGENITORS AT DIAGNOSIS IDENTIFIES CHRONIC PHASE CML AT HIGH RISK FOR BLAST CRISIS TRANSFORMATION

EHA Library, Sin Tiong Ong, 4206710

SAFETY AND EFFICACY OF IBERDOMIDE-BASED QUADRUPLET  FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: THE IDEAL PHASE I/II TRIAL RESULTS

EHA Library, Prashant Kapoor, 4206753

TECLISTAMAB  (TEC) +/- LENALIDOMIDE (LEN) VERSUS LEN ALONE AS MAINTENANCE THERAPY POST-TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED SAFETY RUN-IN (SRI) RESULTS FROM EMN30/MAJESTEC-4

EHA Library, Niels W. C. J. van de donk, 4206751

DARATUMUMAB PLUS BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL ANALYSIS OF TRANSPLANT-INELIGIBLE PATIENTS IN THE PHASE 3 CEPHEUS STUDY

EHA Library, Saad Z Usmani, 4206750

LUSPATERCEPT (LUSPA) INITIATED AT THE MAXIMUM-APPROVED DOSE IN PATIENTS (PTS) WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) WHO REQUIRE TRANSFUSIONS: PRIMARY ANALYSIS FROM MAXILUS

EHA Library, Matteo Giovanni Della, 4206727

OFIRNOFLAST, A FIRST-IN-CLASS NEK7 INHIBITOR, INDUCES ROBUST TRANSFUSION INDEPENDENCE AND MULTILINEAGE HEMATOLOGICAL IMPROVEMENT IN LOWER-RISK MYELODYSPLASTIC SYNDROME(LR-MDS): PHASE 2 RESULTS

EHA Library, VARUN BAFNA, 4206728

TARGETING THE ATYPICAL PROTEIN KINASE WNK1 IN TAL1-RELATED T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Giovanni Roti, 4206659

ONCOGENIC MECHANISMS AND THERAPEUTIC TARGETING OF THE HIGH-RISK CDX2/UBTF B-ALL

EHA Library, Hugo Bergugnat, 4206660

COST-EFFECTIVENESS AND BUDGET IMPACT OF GENE THERAPY FOR ELIGIBLE PATIENTS WITH SICKLE CELL DISEASE IN THE NETHERLANDS

EHA Library, Melanie Bruinooge, 4206883

HEALTH-RELATED QUALITY OF LIFE FOR LONG-TERM SURVIVORS OF CLASSICAL HODGKIN LYMPHOMA WITH AND WITHOUT RELAPSE

EHA Library, Joachim Baech, 4206882

PROGNOSTIC IMPORTANCE OF PRE-TREATMENT HEALTH-RELATED QUALITY OF LIFE AND FITNESS INDICATORS IN OLDER ADULTS WITH ACUTE MYELOID LEUKEMIA. ANALYSIS FROM THE INTERNATIONAL EORTC AML 21 PHASE 3 TRIAL

EHA Library, Fabio Efficace, 4206881

MAPPING RESEARCH AND EQUITY ACROSS EUROPE: FINDINGS FROM THE EUROPEAN ATLAS ON CLINICAL TRIALS IN CANCER AND HAEMATOLOGY (EUROACT)

EHA Library, Lis Puga, 4206880

ASSESSMENT OF NIPOCALIMAB EFFECTS ON FATIGUE IN WARM AUTOIMMUNE HEMOLYTIC ANEMIA: RESULTS FROM THE DOUBLE-BLIND PHASE 2/3 ENERGY TRIAL

EHA Library, Irina Murakhovskaya, 4206879

CIRCULATING TUMOR DNA COMPLEMENTS BONE MARROW GENOTYPING AND TRACKS MRD KINETICS IN MULTIPLE MYELOMA: RESULTS FROM A DSMM XVII COHORT

EHA Library, Philipp Nakov, 4206744

TARGETING MYELOID IMMUNE CHECKPOINTS TO ENHANCE ANTI-MULTIPLE MYELOMA IMMUNITY

EHA Library, Marcello Turi, 4206745

LILRB4 DRIVES IMMUNOSUPPRESSIVE MYELOID CELL FORMATION VIA THE S100A4-CCL3 AXIS TO PROMOTE IMMUNE EVASION IN MULTIPLE MYELOMA

EHA Library, Mu Hao, 4206746

VIRMA EPITRANSCRIPTOMICALLY REGULATES CELL PROLIFERATION, APOPTOSIS, AND MITOCHONDRIAL FUNCTION VIA M6A IN MULTIPLE MYELOMA

EHA Library, Estibaliz Urizar-Compains, 4206747

INTEGRATED PHENOTYPIC CLASSIFICATION OF MULTIPLE MYELOMA USING MULTIMODAL SPATIAL TUMOR BURDEN AND SOLUBLE BCMA: REFINING R-ISS AND CHARACTERIZING BIOLOGICAL DISCORDANCE

EHA Library, Masanori Toho, 4206748

FUNCTIONAL TP53 PHENOTYPE SCORE REFINES PROGNOSTIC STRATIFICATION IN MONOALLELIC TP53-MUTATED MYELODYSPLASTIC NEOPLASMS BEYOND ALLELIC STATE

EHA Library, Alexander Streuer, 4206726

EARLY VERSUS DELAYED ESA IN LOWER-RISK NON -TRANSFUSION-DEPENDENT MDS: FINAL PHASE III EPO-PRETAR RESULTS ON TRANSFUSION DEPENDENCE AND ERYTHROID RESPONSE

EHA Library, Sophie Park, 4206725

CPX-351 VERSUS STANDARD OF CARE AS BRIDGING TO ALLOHCT IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC NEOPLASMS OR OLIGOBLASTIC ACUTE MYELOID LEUKEMIA: RESULTS OF THE RANDOMIZED PHASE 2 PALOMA STUDY

EHA Library, Uwe Platzbecker, 4206724

SAFETY AND EFFICACY OF ELRANATAMAB AS EARLY INTERVENTION IN PATIENTS WITH HIGH-RISK SMOLDERING MYELOMA: FIRST RESULTS FROM THE PHASE 2 ERASMM (EMN34) STUDY

EHA Library, Cyrille Touzeau, 4206759

PHASE 3 RANDOMIZED TRIAL OF ANSELAMIMAB DEMONSTRATES IMPROVEMENT IN ALL-CAUSE MORTALITY IN Κ LIGHT-CHAIN AMYLOIDOSIS

EHA Library, Ashutosh Wechalekar, 4206760

AGGRESSIVE SMOLDERING CURATIVE APPROACH EVALUATING NOVEL THERAPIES (ASCENT): A PHASE 2 TRIAL OF INDUCTION, CONSOLIDATION, AND MAINTENANCE IN HIGH-RISK SMOLDERING MULTIPLE MYELOMA

EHA Library, Shaji Kumar, 4206761

INITIAL EFFICACY AND SAFETY DATA FROM THE PHASE 1/2 LINKER-AL2 STUDY OF LINVOSELTAMAB (LINVO) MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY (RR) SYSTEMIC LIGHT CHAIN (AL) AMYLOIDOSIS

EHA Library, Ashutosh Wechalekar, 4206762

PHASE 1 DOSE ESCALATION SAFETY AND EFFICACY OF ETENTAMIG IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS

EHA Library, Efstathios Kastritis, 4206763

DEVELOPMENT OF A G6B DIRECTED ANTIBODY DRUG CONJUGATE FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Adam Mead, 4206764

ONCOGENIC RAS EXPLOITS A FETAL-RESTRICTED CHROMATIN STATE TO INITIATE JMML VIA CEBPB ACTIVATION

EHA Library, Giulia Orlando, 4206765

CD9 MARKS THE DISEASE-PROPAGATING HEMATOPOIETIC STEM CELL POPULATION IN MYELOFIBROSIS

EHA Library, Lara Tavernari, 4206767

TRANSCRIPTIONAL SUBTYPES OF MYELOFIBROSIS ARE INDEPENDENT OF DRIVER MUTATIONS AND CAPTURE DISTINCT BIOLOGY, OUTCOMES, AND DISEASE TRAJECTORIES

EHA Library, Andy Zeng, 4206768

GENETIC BIOMARKERS PREDICTING SUSTAINED EFFICACY OF VENETOCLAX-BASED THERAPIES OR CIT IN CHRONIC LYMPHOCYTIC LEUKEMIA: FINAL 5‑YEAR ANALYSIS OF THE GAIA/CLL13 TRIAL

EHA Library, Eugen Tausch, 4206703

A PHASE 2 STUDY OF FIXED-DURATION PIRTOBRUTINIB AND OBINUTUZUMAB IN PREVIOUSLY UNTREATED CLL

EHA Library, Inhye E. Ahn, 4206702

COFORMULATED FAVEZELIMAB/PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN PARTICIPANTS WITH RELAPSED OR REFRACTORY CLASSIC HODGKIN LYMPHOMA: RESULTS OF THE RANDOMIZED PHASE 2 KEYFORM-008 STUDY

EHA Library, Guilherme Perini, 4206774

FINAL ANALYSIS OF THE GHSG HD21 OLDER COHORT: EFFICACY, SURVIVAL AND LATE TOXICITY OF PET-GUIDED BRECADD IN OLDER PATIENTS WITH ADVANCED-STAGE CLASSIC HODGKIN LYMPHOMA

EHA Library, Justin Ferdinandus, 4206775

AVELUMAB IN THE FRONT-LINE TREATMENT OF ADVANCED CLASSICAL HODGKIN LYMPHOMA (AVENUE)- FINAL 3-YEAR RESULTS OF PHASE II STUDY

EHA Library, Aisling Barrett, 4206776

INTERIM PET/CT ADAPTED PD-1 INHIBITOR INCORPORATION TO AVOID HIGH-DOSE CHEMOTHERAPY AND RADIOTHERAPY IN CLASSICAL HODGKIN’S LYMPHOMA

EHA Library, Shenmiao Yang, 4206777

ULTRASENSITIVE CTDNA MRD BY PHASED-SEQ COMPLEMENTS PET/CT AND PREDICTS TREATMENT FAILURE IN EARLY AND ADVANCED CLASSIC HODGKIN LYMPHOMA

EHA Library, Jan Lukas Boegeholz, 4206778

ECTOPIC ACTIVATION OF FOXF1 AND FENDRR BY T(14;16)(Q32;Q24) IDENTIFIES A HIGH-RISK T-ALL/MPAL SUBTYPE.

EHA Library, Danika Di Giacomo, 4206661

NOTCHING UP LEUKEMIA-INITIATING CELLS TO ERADICATE T-ALL

EHA Library, Guillaume Andrieu, 4206662

TUNING AND TARGETING CCR9 FOR THE TREATMENT OF T-ALL

EHA Library, Jamie Deyell, 4206663

EPIGENETIC-METABOLIC REPROGRAMMING OF MACROPHAGES BY DECITABINE REMODELS THE POST-TRANSPLANT IMMUNE MICROENVIRONMENT TO PREVENT AML RELAPSE VIA THE H3K4ME3-ACOD1-ITACONATE AXIS

EHA Library, Yutong Xie, 4206669

EARLY T-CELL RECEPTOR REPERTOIRE FEATURES PREDICT LONG-TERM OUTCOME IN PAEDIATRIC IMMUNE THROMBOCYTOPAENIA

EHA Library, Amna Malik, 4206873

RESULTS FROM EPCORE DLBCL-1: RANDOMIZED PHASE 3 STUDY OF EPCORITAMAB (EPCOR) VS INVESTIGATOR’S CHOICE CHEMOIMMUNOTHERAPY (CIT) IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL)

EHA Library, Christopher P. Fox, 4206789

VISPA-CEL, AN ALLOGENEIC ANTI-CD19 CAR-T CELL THERAPY WITH A PD-1 KNOCKOUT, IN PATIENTS WITH RELAPSED/REFRACTORY B CELL NON-HODGKIN LYMPHOMA (ANTLER PHASE 1 CLINICAL TRIAL)

EHA Library, Stephen Schuster, 4206790

POLATUZUMAB VEDOTIN PLUS RITUXIMAB, IFOSFAMIDE, CARBOPLATIN, ETOPOSIDE (POLA-R-ICE) VS R-ICE AS SECOND LINE TREATMENT IN LARGE B CELL LYMPHOMA (LBCL). FINAL ANALYSIS OF A RANDOMIZED PHASE 3 STUDY

EHA Library, Bertram Glass, 4206791

SAFETY DATA AND INITIAL POOLED EFFICACY DATA FROM THE NORDIC LYMPHOMA GROUP PHASE 3 POLAR BEAR TRIAL IN ELDERLY OR FRAIL PATIENTS WITH DIFFUSE LARGE CELL LYMPHOMA - R-POLA-MINI-CHP VS. R-MINI-CHOP

EHA Library, Mats Jerkeman, 4206792

GOLCADOMIDE (GOLCA), A POTENTIAL, FIRST-IN-CLASS ORAL CELMOD + POLA-RCHP IN PATIENTS (PTS) WITH NEWLY DIAGNOSED AGGRESSIVE B-CELL LYMPHOMA (A-BCL): SAFETY AND 12-MONTH EFFICACY FROM A PHASE 1B STUDY

EHA Library, Maria Bouzani, 4206793

OXPLORED: A MULTICENTRE UK-WIDE OBSERVATIONAL STUDY TO IDENTIFY AND PROSPECTIVELY VALIDATE PREDICTORS OF DISEASE PROGRESSION IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) AND MBL

EHA Library, Danmei Xu, 4206701

VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: FINAL RESULTS OF THE RANDOMIZED CLL14 STUDY

EHA Library, Kirsten Fischer, 4206700

FIRST-LINE TREATMENT OF CLL/SLL WITH THE ALL-ORAL COMBINATION OF SONROTOCLAX AND ZANUBRUTINIB ACHIEVES UNDETECTABLE MINIMAL RESIDUAL DISEASE RATES OF >90%, INCLUDING IN PATIENTS WITH DEL(17P)/TP53

EHA Library, Chan Y. Cheah, 4206699

ERG RECONFIGURES A CONTEXT-SPECIFIC LEUKAEMIC 3D ENHANCER LANDSCAPE TO DRIVE AML VIA DIRECT ENHANCER-MACHINERY REPURPOSING AND INDIRECT TRANSCRIPTION FACTOR BLOCKADE

EHA Library, Cécile Lopez, 4206673

ZEB1 DEFINES A TARGETABLE MENIN-INHIBITOR ESCAPE PROGRAM IN KMT2A::MLLT3 AML

EHA Library, Liam MacPhee, 4206672

TARGETING PCYT1A INDUCES SYNTHETIC LETHALITY IN MONOCYTIC AML BY TRIGGERING PEMT-DEPENDENT METABOLIC CATASTROPHE AND ONE-CARBON IMBALANCE

EHA Library, Jakushin Nakahara, 4206671

IMPACT OF PROTOCOL‑MANDATED DOSE HOLDS ON PLATELET RESPONSE DURABILITY IN PEDIATRIC ITP PATIENTS TREATED WITH AVATROMBOPAG: AVA‑301 POST‑HOC ANALYSIS

EHA Library, Amanda Grimes, 4206872

NPM1C REQUIRES SNORNA DEPENDENT CHROMATIN BINDING FOR LEUKEMOGENESIS

EHA Library, Fengbiao Zhou, 4206670

TIME TO PLATELET COUNT RESPONSE AFTER INTRAVENOUS EFGARTIGIMOD IN ADULTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA IN A PHASE 3 CLINICAL TRIAL (ADVANCE IV) AND ITS OPEN-LABEL EXTENSION STUDY (ADVANCE IV+)

EHA Library, Monica Carpenedo, 4206870

PHASE 3 LUNA3 FINAL EFFICACY AND SAFETY RESULTS FOR RILZABRUTINIB IN THE LONG-TERM EXTENSION PERIOD IN ADULTS WITH PERSISTENT/CHRONIC IMMUNE THROMBOCYTOPENIA (ITP)

EHA Library, David Kuter, 4206869

BEYOND PATIENT FACTORS: THE SUBSTANTIAL IMPACT OF SURGEON AND PROCEDURE VARIABILITY ON BLOOD TRANSFUSION RISK

EHA Library, Esa Turkulainen, 4206863

PAIRED PROTEOMIC ANALYSIS OF IN VIVO AND EX VIVO HUMAN ERYTHROID DIFFERENTIATION IDENTIFIES KEY ELEMENTS OF STRESS ERYTHROPOIESIS

EHA Library, Pedro Moura, 4206859

TITLE: RALLY-MF: INITIAL EFFICACY OF A PHASE 2 STUDY OF DISC-0974, AN ANTI-HEMOJUVELIN ANTIBODY, TO TREAT ANEMIA IN MYELOFIBROSIS

EHA Library, Naseema Gangat, 4206860

DIGITAL CAPABILITIES AND TRANSFUSION PRACTICE IN EUROPEAN HOSPITALS: EMERGING FINDINGS FROM THE PAN-EUROPEANTRANSFUSION RESEARCH INFRASTRUCTURE (PETRA) COLLABORATIVE

EHA Library, Hayley G Evans, 4206861

THE COOL SIDE OF PLATELETS: EMERGENCE OF UNIQUE PLATELET SUBPOPULATIONS WITH SPECIFIC FUNCTIONAL PROPERTIES IN COLD-STORED PLATELET CONCENTRATES

EHA Library, Xavier Delabranche, 4206862

Abstract Book 2026

EHA Library, Faculty / Presenters, 4225769

REAL-WORLD DATA ON DOAC USE IN CHILDREN: AN UPDATE FROM THE INTERNATIONAL THROM-PED DOAC REGISTRY

EHA Library, Susanne Holzhauer, 4214965

REAL-WORLD EXPERIENCE OF MITAPIVAT IN PYRUVATE KINASE DEFICIENCY

EHA Library, Giacinto Luca Pedone, 4206856

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ESLIM-02 FOR EFFICACY AND SAFETY OF SOVLEPLENIB (HMPL-523) IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA IN CHINA

EHA Library, Bing Han, 4206855

NIPOCALIMAB FOR WARM AUTOIMMUNE HEMOLYTIC ANEMIA: RESULTS FROM THE PHASE 2/3 RANDOMIZED DOUBLE-BLIND ENERGY STUDY

EHA Library, Bruno Fattizzo, 4206854

MAPPING HEMATOPOIETIC STEM CELL NICHE INTERACTIONS AT SINGLE-CELL AND CLONAL RESOLUTION IDENTIFIES ALTERED CROSSTALK AND NOVEL TARGETS: Β-THALASSEMIA AS A CASE STUDY OF INHERITED BLOOD DISORDERS

EHA Library, Annamaria Aprile, 4206833

CLINICALLY RELEVANT SUBGROUP ANALYSIS FROM THE RANDOMIZED PHASE 3 EPCORE FL-1 TRIAL: TREATMENT (TX) EFFECT OF EPCORITAMAB WITH LENALIDOMIDE AND RITUXIMAB (R²) IN R/R FOLLICULAR LYMPHOMA (FL)

EHA Library, Benoit Tessoulin, 4206783

SUROVATAMIG (AZD0486) PLUS RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (FL): INITIAL SAFETY DATA FROM THE PHASE 3 SOUNDTRACK-F1 TRIAL

EHA Library, Chan Y. Cheah, 4206782

GOLCADOMIDE (GOLCA), A POTENTIAL, FIRST-IN-CLASS, ORAL CELMOD ±RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PHASE (PH) 1/2 STUDY LONG-TERM FOLLOW-UP (F/U)

EHA Library, Daniel Morillo, 4206781

SAFETY AND EFFICACY OF SUBCUTANEOUS MOSUNETUZUMAB PLUS LENALIDOMIDE INDUCTION THERAPY FOLLOWED BY MOSUNETUZUMAB MAINTENANCE IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA

EHA Library, Emmanuel Bachy, 4206780

MOSUNETUZUMAB FOR EARLY RELAPSE OF FOLLICULAR LYMPHOMA IN THE NORDIC COUNTRIES (MERLIN, NLG-FL6/ML43841)

EHA Library, Marianne Brodtkorb, 4206779

BTL-101, A FULLY HUMAN TRISPECIFIC BCMA×GPRC5D×CD3 T-CELL ENGAGER FOR THE TREATMENT OF MULTIPLE MYELOMA

EHA Library, Jiansong Yang, 4206743

DEVELOPMENT OF BMS-986453, A DUAL-TARGETING BCMA×GPRC5D CHIMERIC ANTIGEN RECEPTOR (CAR) FOR THE TREATMENT OF MULTIPLE MYELOMA

EHA Library, Doris Hansen, 4206742

AZD0120, A DUAL BCMA/CD19 CAR-T CELL THERAPY, DEMONSTRATES A NAIVE/CENTRAL MEMORY PHENOTYPE AND INDUCES A RAPID DECLINE IN SOLUBLE BCMA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Binod Dhakal, 4206741

SUCCESSFUL IN VIVO CAR-T GENERATION AND MINIMAL RESIDUAL DISEASE (MRD) CLEARANCE WITH KLN-1010 ACROSS DIVERSE BASELINE T CELL PHENOTYPES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Andrew Spencer, 4206739

EARLY BONE FRAGILITY IS ASSOCIATED WITH VASCULAR ABNORMALITIES IN TELOMERE BIOLOGY DISORDERS: FINDINGS FROM THE MULTICENTER, INTERNATIONAL INSIGHT STUDY

EHA Library, Jane Koo, 4206733

LONG-TERM OUTCOMES IN PATIENTS WITH RELAPSED OR REFRACTORY SEVERE APLASTIC ANEMIA

EHA Library, Fieke Hoff, 4206732

DISTINCT IMMUNE DIVERSITY OF CD8+ T CELLS DEFINES PEDIATRIC HEPATITIS-ASSOCIATED APLASTIC ANEMIA AND SEVERE APLASTIC ANEMIA

EHA Library, Lixian Chang, 4206731